Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma

Bone Marrow Transplantation

Volumn 37, Issue 1, 2006, Pages 65-72

  Gojo, I ^a   Meisenberg, B ^a   Guo, C ^a   Fassas, A ^b   Murthy, A ^a   Fenton, R ^a   Takebe, N ^a   Heyman, M ^a   Philips, G L ^c   Cottler Fox, M ^b   Sarkodee Adoo, C ^d   Ruehle, K ^a   French, T ^a   Tan, M ^a   Tricot, G ^a   Rapoport, A P ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d City of Hope Samaritan BMT Program   (United States)

Author keywords

Autotransplant; Consolidation chemotherapy; Multiple myeloma; Post transplant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MELPHALAN; MESNA; PACLITAXEL; PREDNISONE; STEROID; VINCRISTINE;

ABDOMINAL ABSCESS; ABDOMINAL WALL; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CATHETER INFECTION; COLITIS; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DIARRHEA; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYCOSIS; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RETINITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REACTIVATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 31344455109     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705192     Document Type: Article

References (34)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Harousseau JL, Shaughnessy Jr J, Richardson P. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2004, 237-256.
4. Barille-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG et al. Advances in biology and therapy of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2003, 248-278.
5. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
6. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
7. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
8. Munshi NC, Desikan KR, Jagannath S, Siegel D, Bracy D, Tricot G et al. Dexamethasone, cyclophosphamide, etoposide and cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT). Blood 1996; 2331: 586a.
9. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace Jr AJ, Hohn KW et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275: 343-349.
10. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802-809.
11. Haldar S, Jena N, Croce CM. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation. Biochem Cell Biol 1994; 72: 455-462.
12. Miguel-Garcia A, Orero T, Matutes E, Carbonell F, Miguel-Sosa A, Linares M et al. Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: A comparative study. Haematologica 1998; 83: 298-304.
13. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
14. Gojo I, Guo C, Sarkodee-Adoo C, Meisenberg B, Fassas A, Rapoport AP et al. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: Efficacy and toxicity. Bone Marrow Transplant 2004; 34: 69-76.
15. Fassas AB, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B et al. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 2002; 119: 164-168.
16. Rapoport AP, Guo C, Badros A, Hakimian R, Akpek G, Kiggundu E et al. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004; 34: 883-890.
17. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002; 29: 303-312.
18. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
19. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
20. Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001; 112: 814-819.
21. Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446.
22. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-735.
23. Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs MJ et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10: 8170-8176.
24. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172.
25. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
26. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: An emerging new therapy in myeloma. J Clin Oncol 2004; 22: 3212-3214.
27. Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79: 875-882.
28. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
29. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
30. Barlogie B. Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience. Semin Hematol 2003; 40: 33-38.
31. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
32. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
33. Borrello I, Bierdrzycki B, Sheets N, George B, Racke F, Loper K et al. Autologous tumor combined with a GM-CSF-secreting cell line vaccine (GVAX) following autologous stem cell transplant (ASCT) in multiple myeloma. Blood 2004; 440: 126a.
34. Rapoport A, Stadtmauer EA, Levine BL, Badros A, Akpek G, Cotte J et al. Adoptive transfer of ex vivo costimulated autologous T-cells in conjuction with pneumococcal conjugate vaccine immunizations accelerates post-transplant T-cell recovery after autotransplantation for myeloma: results of a randomized study. Blood 2004; 439: 126a.